Resultados globales: 9 registros encontrados en 0.02 segundos.
Artículos, Encontrados 9 registros
Artículos Encontrados 9 registros  
1.
8 p, 594.7 KB The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes : Achieving HbA1c targets with basal insulin in a real-world setting / Meneghini, Luigi F. (Parkland Health & Hospital System) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Orsi, Emanuela (Fondazione Ca' Granda IRCCS) ; Lalic, Nebojsa M. (University of Belgrade) ; Cali, Anna M.G. (Sanofi) ; Westerbacka, Jukka (Sanofi) ; Stella, Peter (Sanofi) ; Candelas, Christophe (Sanofi) ; Pilorget, Valerie (Sanofi) ; Perfetti, Riccardo (Sanofi) ; Khunti, Kamlesh (University of Leicester) ; Universitat Autònoma de Barcelona
To describe in a real-world setting the achievement of physician-selected individualized HbA1c targets in individuals with type 2 diabetes, newly or recently initiated with basal insulin, and the association of hypoglycaemia with target achievement. [...]
2019 - 10.1111/dom.13673
Diabetes, Obesity and Metabolism, Vol. 21 Núm. 6 (june 2019) , p. 1429-1436  
2.
12 p, 1.0 MB The importance of the initial period of basal insulin titration in people with diabetes / Khunti, Kamlesh (University of Leicester) ; Giorgino, F. (University of Bari Aldo Moro) ; Berard, L. (Winnipeg Regional Health Authority) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Harris, S.B. (Western University) ; Universitat Autònoma de Barcelona
Achieving target glycaemic control is essential in people with diabetes to minimize the risk of long-term complications, and many people with type 2 diabetes will ultimately require basal insulin (BI) therapy to achieve their individualized glycaemic targets. [...]
2020 - 10.1111/dom.13946
Diabetes, Obesity and Metabolism, Vol. 22 Núm. 5 (january 2020) , p. 722-733  
3.
17 p, 389.2 KB Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis / Gourdy, Pierre (Université de Toulouse) ; Bonadonna, Riccardo C. (University of Parma) ; Freemantle, Nick (University College London) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Müller-Wieland, Dirk (University Hospital Aachen (Alemanya)) ; Bigot, Gregory (IVIDATA) ; Mauquoi, Celine (IDDI) ; Ciocca, Alice (General Medicines. Sanofi) ; Bonnemaire, Mireille (General Medicines. Sanofi)
Introduction: Gender differences in risk factors and treatment outcomes for type 2 diabetes mellitus (T2DM) may exist. We used the REALI European database to investigate whether there were gender-specific differences in baseline characteristics and clinical outcomes among patients with inadequately controlled T2DM initiated on insulin glargine 300 U/ml (Gla-300). [...]
2022 - 10.1007/s13300-021-01179-8
Diabetes Therapy, Vol. 13 Núm. 1 (january 2022) , p. 57-73  
4.
25 p, 618.2 KB Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL : Results from the REALI European Pooled Data Analysis / Bonadonna, Riccardo C (University of Parma) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Müller-Wieland, Dirk (University Hospital Aachen (Alemanya)) ; Freemantle, Nick (University College London) ; Bigot, Gregory (IVIDATA Group) ; Mauquoi, Celine (International Drug Development Institute (IDDI)) ; Ciocca, Alice (Sanofi) ; Bonnemaire, Mireille (Sanofi) ; Gourdy, Pierre (Université de Toulouse)
Introduction: Patients aged ≥ 65 years continue to be underrepresented in clinical studies related to type 2 diabetes mellitus (T2DM). Accordingly, the REALI pooled analysis was performed to evaluate the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) across different age subgroups, using data from 14 interventional and non-interventional studies. [...]
2021 - 10.1007/s13300-021-01030-0
Diabetes Therapy, Vol. 12 Núm. 4 (april 2021) , p. 1073-1097  
5.
10 p, 1.3 MB Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area : A retrospective cohort study / Vlacho, Bogdan (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Mundet-Tudurí, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Mata-Cases, M. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Vallès-Callol, J.A. (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Real, J. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cos Claramunt, Francesc Xavier (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Khunti, K. (Diabetes Research Centre. University of Leicester) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Franch-Nadal, J. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Universitat Autònoma de Barcelona
Aim: To compare the changes in HbA1c, the effect on body weight or both combined after the addition of a DPP-4i, SGLT-2i, or sulfonylureas (SU) to metformin in real-world condition. Methods: We used a primary care SIDIAP database. [...]
2021 - 10.1016/j.diabres.2020.108616
Diabetes research and clinical practice, Vol. 171 (january 2021) , p. 108616  
6.
17 p, 890.5 KB Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes : Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia / Franch-Nadal, Josep (Institut Català de la Salut) ; Mata-Cases, Manel (Institut Català de la Salut) ; Ortega, Emilio (Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición) ; Real, Jordi (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Gratacòs, Mònica (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Vlacho, Bogdan (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Vallés, Joan Antoni (Institut Català de la Salut) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
To assess the clinical characteristics, the prescription pattern of GLP-1 receptor agonists (GLP-1RA) users, and HbA1c and weight change, we retrospectively assessed patients with type 2 diabetes by initiating GLP-1RA as an add-on to the standard of care in Catalonia. [...]
2019 - 10.3390/jcm8091389
Journal of clinical medicine, Vol. 8 (september 2019)  
7.
15 p, 785.4 KB Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus : DosInGlar Study / Duque, Natalia (Departamento Médico, Lilly Alcobendas) ; Artime, Esther (Departamento Médico, Lilly Alcobendas) ; Romera, Irene (Departamento Médico, Lilly Alcobendas) ; Lebrec, Jeremie (HaaPACS GmbH, Schriesheim, Germany) ; Díaz, Silvia (Departamento Médico, Lilly Alcobendas) ; Rubio, Miriam (Departamento Médico, Lilly Alcobendas) ; Sicras Mainar, Antoni (Atrys Health SA, Health Economics and Outcomes Research) ; Carretero Anibarro, Enrique (Medicina Familiar y Comunitaria, Unidad de Gestión Clínica Estepa) ; Mundet-Tudurí, Xavier (Universitat Autònoma de Barcelona) ; Gorgojo Martínez, Juan José (Hospital Universitario Fundación Alcorcón) ; Reviriego, Jesús (Departamento Médico, Lilly Alcobendas)
In the EDITION clinical trial programme, patients with type 2 diabetes mellitus (T2DM) receiving insulin glargine (IGlar) U300 required 10-15% more insulin than those receiving IGlar U100. This study sought to determine whether this difference was apparent in real-world practice. [...]
2021 - 10.1007/s12325-021-01773-z
Advances in Therapy, Vol. 38 (may 2021) , p. 3857-3871  
8.
8 p, 1.1 MB Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial / Wysham, Carol (Rockwood Clinic (Spokane, Washington)) ; Bonadonna, Riccardo C (University of Parma) ; Aroda, Vanita R. (Medstar Health Research Institute (Hyattsville, Maryland)) ; Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Kapitza, Christoph (Profil Institute (Neuss, Alemanya)) ; Stager, William (Sanofi) ; Yu, Christine (Sanofi) ; Niemoeller, Elisabeth (Sanofi) ; Souhami, Elisabeth (Sanofi) ; Bergenstal, Richard M. (International Diabetes Center (Minneapolis, Estats Units)) ; Universitat Autònoma de Barcelona
Aims: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose-lowering drugs. [...]
2017 - 10.1111/dom.12961
Diabetes, Obesity and Metabolism, Vol. 19 (2017) , p. 1408-1415  
9.
10 p, 889.7 KB Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA / Mauricio Puente, Dídac (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Meneghini, Luigi (University of Texas Southwertern Medical Center) ; Seufert, Jochen (Freiburg Universität) ; Liao, Laura (Sanofi, Bridgewater, New Jersey) ; Wang, Hongwei (Sanofi, Bridgewater, New Jersey) ; Tong, Liyue (Sanofi, Bridgewater, New Jersey) ; Cali, Anna M.G (Sanofi, Paris) ; Stella, Peter (Sanofi, Paris) ; Carita, Paulo (Sanofi, Paris) ; Khunti, Kamlesh (University of Leicester. Diabetes Research Centre) ; Universitat Autònoma de Barcelona
Aims: To evaluate short- and long-term glycaemic control and hypoglycaemia incidence in insulin-naïve patients ≥30 years of age with type 2 diabetes (T2DM) initiating basal insulin (BI) with or without oral anti-hyperglycaemic drugs (OADs). [...]
2017 - 10.1111/dom.12927
Diabetes, Obesity and Metabolism, Núm. 19 (2017) , p. 1155-1164  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.